Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer

John K. Chan, Mark F. Brady, Richard T. Penson, Helen Huang, Michael J. Birrer, Joan L. Walker, Paul A. Disilvestro, Stephen C. Rubin, Lainie P. Martin, Susan A. Davidson, Warner K. Huh, David M. O'Malley, Matthew P. Boente, Helen Michael, Bradley J. Monk

Research output: Contribution to journalComment/debate

Original languageEnglish (US)
Pages (from-to)344-345
Number of pages2
JournalObstetrical and Gynecological Survey
Volume71
Issue number6
DOIs
StatePublished - Jun 1 2016

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., Disilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., Huh, W. K., O'Malley, D. M., Boente, M. P., Michael, H., & Monk, B. J. (2016). Weekly Versus Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. Obstetrical and Gynecological Survey, 71(6), 344-345. https://doi.org/10.1097/OGX.0000000000000328